The state of Illinois currently has 124 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
Recruiting
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Saint Anthony's Health, Alton, Illinois +36 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Recruiting
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/08/2023
Locations: Northshore University Health System, Evanston, Illinois
Conditions: Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
Recruiting
This study is aimed to establish a registry of women undergoing intensive surveillance for the early detection of breast cancer in high-risk women.
Gender:
Female
Ages:
25 years and above
Trial Updated:
08/01/2023
Locations: University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Breast Cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/30/2023
Locations: Illinois Cancer Specialists - Arlington Heights, Arlington Heights, Illinois
Conditions: Breast Cancer
Empowering Latinas to Obtain Guideline Concordant Screenings
Recruiting
The design builds on past studies by integrating social network analysis (SNA) and implementation science (IS) into a longitudinal randomized clinical trial (RCT). The investigator will compare the long-term effects of interventions by examining guideline-concordant initial and repeat Brease Cancer (BC) screening.
Gender:
Female
Ages:
Between 50 years and 74 years
Trial Updated:
06/29/2023
Locations: Mile Square Health Center, Chicago, Illinois +1 locations
Conditions: Breast Cancer Screening
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
Recruiting
This is single arm study of a window of opportunity in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive lenvatinib 12 mg daily for 7 and pembrolizumab 200 mg IV on day 1 prior to surgery
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/26/2023
Locations: University of Illinois, Chicago, Illinois
Conditions: Triple Negative Breast Cancer
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
Recruiting
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 site... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Carle Cancer Center, Urbana, Illinois
Conditions: Metastatic Breast Cancer
Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy
Recruiting
Patients will be randomly assigned to one of two groups: the group exposed to NS, or the standard care group exposed to supportive dialogue. Patients assigned to the former group will be exposed to continuous NS throughout the CNB procedure.
Gender:
Female
Ages:
21 years and above
Trial Updated:
04/26/2023
Locations: University of Chicago, Chicago, Illinois
Conditions: Breast Cancer
Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors
Recruiting
The purpose of this study is to test the feasibility of implementing acupuncture intervention in federally qualified health centers oncology clinics for breast cancer survivors.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/23/2023
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Breast Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Recruiting
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2023
Locations: Northwestern Univeristy, Chicago, Illinois
Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: Cancer Care Specialists of Central Illinois, Decatur, Illinois +1 locations
Conditions: HER2-negative Breast Cancer
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
Recruiting
This clinical trial assesses if the use of a three-dimensional imaging device called the Clarix Imaging Volumetric Specimen Imager (VSI) can help guide and assist surgeons in identifying and removing all positive margins while in the operating room (intraoperative imaging) for patients with breast cancer and breast ductal carcinoma in situ. Breast conservation surgery or lumpectomy is a standard of care (routine) procedure that removes the tumor and a rim of surrounding normal tissue (margins) w... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/30/2022
Locations: Northwestern University, Chicago, Illinois
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Bilateral Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8